Flanagan, William; Whiteman, Gail - In: Journal of Business Ethics 73 (2007) 1, pp. 65-75
At the end of the 1990s, Brazil was faced with a potentially explosive HIV/AIDS epidemic. Through an innovative and multifaceted campaign, and despite initial resistance from multinational pharmaceutical companies, the government of Brazil was able to negotiate price reductions for HIV...